Evidence map›Paper›PMID 27117066›Full record

ArticleJournal of neuroinflammation2016

Methamphetamine alters microglial immune function through P2X7R signaling.

Nicole C Fernandes, Uma Sriram, Larisa Gofman, Jonathan M Cenna, Servio H Ramirez, Raghava Potula

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 53 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Role of Microglia in Psychostimulant Addiction.Current neuropharmacology · 2023
    Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Agonists, Antagonists, and Modulators of P2X7 Receptors.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Nicole C FernandesDepartment of Pathology and Laboratory Medicine, Lewis Katz School of Medicine at Temple University, MERB 845A, 3500 N. Broad Street, Philadelphia, 19140, PA, USA.
Uma SriramDepartment of Pathology and Laboratory Medicine, Lewis Katz School of Medicine at Temple University, MERB 845A, 3500 N. Broad Street, Philadelphia, 19140, PA, USA.
Larisa GofmanDepartment of Pathology and Laboratory Medicine, Lewis Katz School of Medicine at Temple University, MERB 845A, 3500 N. Broad Street, Philadelphia, 19140, PA, USA.
Jonathan M CennaDepartment of Pathology and Laboratory Medicine, Lewis Katz School of Medicine at Temple University, MERB 845A, 3500 N. Broad Street, Philadelphia, 19140, PA, USA.
Servio H RamirezDepartment of Pathology and Laboratory Medicine, Lewis Katz School of Medicine at Temple University, MERB 845A, 3500 N. Broad Street, Philadelphia, 19140, PA, USA.
Raghava PotulaDepartment of Pathology and Laboratory Medicine, Lewis Katz School of Medicine at Temple University, MERB 845A, 3500 N. Broad Street, Philadelphia, 19140, PA, USA. raghava.potula@tuhs.temple.edu.
Temple University · US

Funding

Pilot Projects Core (PPC)P30DA013429 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI Anjali M Rajadhyaksha · 2000 to 2026
$34.6M
TRAINING PROGRAM: DRUGS OF ABUSE RELATED NEUROPEPTIDEST32DA007237 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI ELLEN M UNTERWALD · 1988 to 2026
$10.6M
Novel serological biomarkers for BBB dysfunction during HIV-1 infectionR01NS086570 · NINDS · TEMPLE UNIV OF THE COMMONWEALTH · PI RAMIREZ, SERVIO HEYBERT · 2013 to 2017
$1.9M
Mechanism of immune dysregulation secondary to methamphetamine abuse.R01DA031064 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI POTULA, RAGHAVA · 2010 to 2014
$1.8M
Role of kallikreins in lupusR03AR065157 · NIAMS · TEMPLE UNIV OF THE COMMONWEALTH · PI SRIRAM, UMA · 2014 to 2016
$234k
NIAMS NIH HHS 1R03AR065157-01A1NIAMS NIH HHS R03 AR065157NIDA NIH HHS P30 DA013429NIDA NIH HHS R01 DA031064NIDA NIH HHS T32 DA007237NINDS NIH HHS R01 NS086570NINDS NIH HHS R01 NS086570-01
6 · The paper itself

Abstract

backgroundPurinoceptors have emerged as mediators of chronic inflammation and neurodegenerative processes. The ionotropic purinoceptor P2X7 (P2X7R) is known to modulate proinflammatory signaling and integrate neuronal-glial circuits. Evidence of P2X7R involvement in neurodegeneration, chronic pain, and chronic inflammation suggests that purinergic signaling plays a major role in microglial activation during neuroinflammation. In this study, we investigated the effects of methamphetamine (METH) on microglial P2X7R.

methodsESdMs were used to evaluate changes in METH-induced P2X7R gene expression via Taqman PCR and protein expression via western blot analysis. Migration and phagocytosis assays were used to evaluate functional changes in ESdMs in response to METH treatment. METH-induced proinflammatory cytokine production following siRNA silencing of P2X7R in ESdMs measured P2X7R-dependent functional changes. In vivo expression of P2X7R and tyrosine hydroxylase (TH) was visualized in an escalating METH dose mouse model via immunohistochemical analysis.

resultsStimulation of ESdMs with METH for 48 h significantly increased P2X7R mRNA (*p < 0.0336) and protein expression (*p < 0.022). Further analysis of P2X7R protein in cellular fractionations revealed increases in membrane P2X7R (*p < 0.05) but decreased cytoplasmic expression after 48 h METH treatment, suggesting protein mobilization from the cytoplasm to the membrane which occurs upon microglial stimulation with METH. Forty-eight hour METH treatment increased microglial migration towards Fractalkine (CX3CL1) compared to control (****p < 0.0001). Migration toward CX3CL1 was confirmed to be P2X7R-dependent through the use of A 438079, a P2X7R-competitive antagonist, which reversed the METH effects (****p < 0.0001). Similarly, 48 h METH treatment increased microglial phagocytosis compared to control (****p < 0.0001), and pretreatment of P2X7R antagonist reduced METH-induced phagocytosis (****p < 0.0001). Silencing the microglial P2X7R decreased TNF-α (*p < 0.0363) and IL-10 production after 48 h of METH treatment. Additionally, our studies demonstrate increased P2X7R and decreased TH expression in the striata of escalating dose METH animal model compared to controls.

conclusionsThis study sheds new light on the functional role of P2X7R in the regulation of microglial effector functions during substance abuse. Our findings suggest that P2X7R plays an important role in METH-induced microglial activation responses. P2X7R antagonists may thus constitute a novel target of therapeutic utility in neuroinflammatory conditions by regulating pathologically activated glial cells in stimulant abuse.

Indexed as

Amphetamine-Related DisordersAnimalsBlotting, WesternCentral Nervous System StimulantsDisease Models, AnimalGene Knockdown TechniquesImmunohistochemistryMaleMethamphetamineMiceMice, Inbred C57BLMicrogliaReal-Time Polymerase Chain ReactionReceptors, Purinergic P2X7Signal TransductionCentral Nervous System StimulantsMethamphetamineReceptors, Purinergic P2X7MethamphetamineMicrogliaPurinergic receptor X7

Identifiers

PMID27117066
PMCPMC4847215
OpenAlexW2342768483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.